|
|
Trenbolone Acetate
| Substance:
Trenbolone Acetate |
| Description;
Dose; Brand Name: Trenbolone
Acetate; 75 mg/cc; QV
|
|
| Trenbolone acetate is a potent
androgenic steroid.
This is the same drug which was once available as an
injectable in the U.S., labeled Finaject, although it's
production has been discontinued here and worldwide for
about a decade. Finaplix was the last remaining pure
trenbolone acetate, however it too had now been
discontinued and replaced with Revalor, trenbolone acetate
with a small amount of estradiol, an estrogen (see Revalor).
Trenbolone acetate is a potent androgen, which will not
readily convert to estrogen. Since in this case it is in
the form of a cattle implant, administration is a bit
difficult. Most commonly, these implant pellets are ground
up and mixed with a 50/50 water/DMSO mix and applied to
the skin daily. This homebrew transdermal mix is very
effective, as seen in Finaplix's popularity. Some a little
more daring have mixed their own Bi-weekly (or more
frequent) injections, although I couldn't see this being a
very sanitary practice. Either when applied to the skin,
or injected, users report great strength and mass gains
with no gyno or water retention. Along with being a strong
muscle-building steroid, it is also noted as being very
effective at burning fat. This has made it very appealing
for competitive athletes looking to shed fat, while at the
same time trying to avoid water retention and keep the
hard physique, which a strong androgen helps bring about.
It should be noted that this is not a beginner's steroid.
Finaplix can be very toxic, especially to the kidneys.
Since this is a strong androgen, related side effects such
as acne and increased aggression are also very common. To
be cautious, users will commonly limit their use of this
drug to 4 or 6 weeks. Finaplix is still available through
some suppliers such as QV and is not being controlled as a
steroid. It will not be long before old lots are exhausted
and pure trenbolone acetate will once again disappear. |
|
|
